TAVR or SAVR
A glimpse into the future

Örjan Friberg

Örebro University Hospital
Sweden
“Prediction is very difficult, especially if it’s about the future.”
— Niels Bohr
Conflicts of interest

- None
“If in the last few years you haven’t discarded a major opinion or acquired a new one, check your pulse. You may be dead.”

My interpretation:
Always be prepared to change your mind!
Even consider it a sign of intelligence …

Galett Burgess 1866 - 1951
"If in the Last Few Years You Haven’t Discarded a Major Opinion or Acquired a New One, Check Your Pulse. You May Be Dead"

My interpretation:
Always be prepared to change your mind!
Even consider it a sign of intelligence …

In 2007, I was convinced TAVR would never work!

I WAS WRONG!!
TAVR

• First-in-man in 2002

• CE-mark in 2007 (CoreValve and Edwards-SAPIEN)
Figure 4 Commercially available and investigational devices for transcatheter aortic valve implantation

Images reprinted with permission from the companies indicated in the Figure.

Figure 1. Number of TAVI procedures, per centre and year, 2008–2017.

The total number of TAVI procedures increased by 27% to 842 in 2017. Details on the numbers of procedures can also be found in Table 1. Karolinska had over 200 procedures, Uppsala, Lund, Linköping, and Sahlgrenska had over 100 cases each, whereas Umeå, Örebro, and Karlskrona had less than 100 cases each.
Figure 1. Number of TAVI procedures, per centre and year, 2008–2017.

The total number of TAVI procedures increased by 27% to 842 in 2017. Details on the numbers of procedures can also be found in Table 1. Karolinska had over 200 procedures, Uppsala, Lund, Linköping, and Sahlgrenska had over 100 cases each, whereas Umeå, Örebro, and Karlskrona had less than 100 cases each.
## Trials, trials….

<table>
<thead>
<tr>
<th>Project</th>
<th>Risk Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARTNER</td>
<td>RCT- high risk</td>
</tr>
<tr>
<td>PARTNER 2</td>
<td>RCT- intermediate</td>
</tr>
<tr>
<td>PARTNER 3</td>
<td>RCT- low risk</td>
</tr>
<tr>
<td>SURTAVI</td>
<td>RCT- intermediate risk</td>
</tr>
<tr>
<td>NOTION</td>
<td>RCT- low risk &gt;70 y. (Presented, not published!)</td>
</tr>
<tr>
<td>NOTION 2</td>
<td>RCT- low risk, ongoing</td>
</tr>
<tr>
<td>Evolut Low Risk</td>
<td>RCT- ongoing</td>
</tr>
<tr>
<td>REPRISE III</td>
<td>Lotus vs Evolut/Corevalve</td>
</tr>
</tbody>
</table>
PARTNER II
Edwards Sapien, Intermediate risk
Results in summary

- TAVR at least equal to SAVR in high risk patients
- TAVR at least equal to SAVR in “intermediate” risk patients
- TAVR seems to be equal to SAVR in low risk patients

* FUTURE LOOKS BRIGHT FOR TAVR, NO DOUBT *
The end of SAVR?
Some questions remain!

- NO LONG TERM RESULTS
Some questions remain!

- **NO LONG TERM RESULTS**
- **Pacemaker** incidence. Linked to long term mortality?
Some questions remain!

- **NO LONG TERM RESULTS**
- Pacemaker incidence. Linked to long term mortality?
- Thrombogenicity? DAPT not efficient. NOAC not working(?)
Some questions remain!

- **NO LONG TERM RESULTS**
- **Pacemaker** incidence. Linked to long term mortality?
- **Thrombogenicity**? DAPT not efficient. NOAC not working.
- Increased risk for **endocarditis**? (11% @5 years in NOTION)
Some questions remain!

- **NO LONG TERM RESULTS**
- **Pacemaker** incidence. Linked to long term mortality?
- **Thrombogenicity**? DAPT not efficient. NOAC not working.
- Increased risk for **endocarditis**? (11% @5years in NOTION)
- Other **indications** than AS?
Some questions remain!

- **NO LONG TERM RESULTS**
- **Pacemaker** incidence. Linked to long term mortality?
- **Thrombogenicity**? DAPT not efficient. NOAC not working.
- Increased risk for **endocarditis**? (11% @5years in NOTION)
- Other **indications** than AS?
- **Technical setbacks** will occur along the way. (Lotus valve presently recalled.)
Some questions remain!

- **NO LONG TERM RESULTS**
- **Pacemaker** incidence. Linked to long term mortality?
- **Thrombogenicity**? DAPT not efficient. NOAC not working.
- Increased risk for **endocarditis**? (11% @5years in NOTION)
- Other **indications** than AS?
- **Technical setbacks** will occur along the way. (Lotus valve presently recalled.)
- The **cost**...
Figure 33. Number of aortic valve procedures, isolated or concomitant CABG, 2007–2017.

Interestingly, the number of isolated aortic valve procedures still seems unaffected by the continuous increase in TAVI procedures.
**Fig. 5** Isolated aortic valve replacement and transcatheter aortic valve implantation (TAVI) The annual count of TAVI submitted to the voluntary registry of German Society for Thoracic and Cardiovascular Surgery does not represent all TAVI procedures performed in Germany in 2016.  

1 Additional TAVI procedures calculated from the German legal quality assurance program, § 137 SGB V.
• We tend to “over-extrapolate” current trends into the future
• We tend to pay more attention to alarmists than to thoughtful, knowledgeable opinions
• Companies, interest groups and activists often have a personal interest in exaggerating

=> Stay calm. Do not “follow the crowd”. Look at facts!
The future?

- Technical development will continue
- New issues will arise along the way
- TAVR volumes will keep increasing
- Some decrease in numbers of isolated SAVR
- Marginal effect on total volumes of cardiac surgery
- Best TAVR results in centers with fairly high volumes and a multidisciplinary approach. Heart team!
- TAVR will/should be considered natural part of cardiac surgery
“If in the last few years you haven’t discarded a major opinion or acquired a new one, check your pulse. You may be dead.”

But I have been wrong before....

Galett Burgess 1866 - 1951
Thank you